Date published: 2026-7-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

UGT2B4 CRISPR/Cas9 KO Plasmid (h): sc-404208

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • UGT2B4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UGT2B4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    UGT2B4 CRISPR/Cas9 KO Plasmid (h)

    sc-404208
    20 µg
    $397.00

    Overview

    UGT2B4 encodes a human UDP-glucuronosyltransferase that catalyzes glucuronidation of endogenous steroids and bile acid–related metabolites as well as diverse xenobiotics, increasing their solubility for elimination. This phase II conjugation activity integrates with hepatic and intestinal detoxification networks and interfaces with nuclear receptor–regulated pathways that coordinate metabolic homeostasis and chemical stress responses. Variation in UGT2B4 expression or activity can shift steroid and bile acid handling and alter clearance of small-molecule substrates, impacting exposure–response relationships in pharmacology. Accordingly, UGT2B4 is studied in the context of metabolism-associated phenotypes and tissue-specific differences in biotransformation capacity.

    UGT2B4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UGT2B4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UGT2B4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UGT2B4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UGT2B4 protein expression.

    This CRISPR knockout system enables efficient generation of UGT2B4-deficient cell models for investigation of UGT2B4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting UGT2B4 exon(s) critical for UGT2B4 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple UGT2B4 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by UGT2B4 CRISPR/Cas9 KO Plasmid (h) and UGT2B4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UGT2B4 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by UGT2B4 HDR Plasmid (h) and UGT2B4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UGT2B4 homology arms to support homology-directed repair at defined UGT2B4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.